GU Cancers 2021 | Latest genomic insights for prostate cancer treatment

Robert Jones, MD, PhD, University of Glasgow & Beatson West of Scotland Cancer Centre, Glasgow, UK, discusses the role of genomics in prostate cancer, highlighting results from the Phase III PROfound trial (NCT02987543). The PROfound trial demonstrated the activity of olaparib in patients with BRCA mutations. Prof. Jones highlights results based on circulating tumor DNA (ctDNA) which may enable routine assessment of somatic mutations using only a blood test. This interview took place during the 2021 Genitourinary Cancers Symposium.